CFC-propelled inhalers to be passé; Generics makers rush for Indian patents; and much more

> The FDA alerted doctors, pharmacists and asthma patients that inhalers using chloroflurocarbons, or CFC, as propellants will no longer be sold in the U.S. after Dec. 31. Report

> Generics makers are joining the rush to seek Indian patents for their products; global and domestic generics companies, which have traditionally focused on manufacturing off-patent drugs, are claiming exclusivity for a large number of drugs. Report

> Federal regulators approved Abiomed's heart implant used to maintain blood flow in heart failure patients during and after surgery. Report

> Watson Pharmaceuticals got the FDA nod for its version of AstraZeneca's heartburn drug Prilosec in a delayed-release capsule; it intends to launch during the third quarter. Release

> GlaxoSmithKline announced today that it had completed its tender offer for Sirtris Pharmaceuticals. Report

> In an effort to streamline its business and save cash, Pharmacopeia is laying off 15 percent of its workforce and decreasing "other expenses through improved operational efficiencies and increased financial discipline." Layoff report

> With help from technology entrepreneur Dr. Yalcin Ayasli, Cambridge, MA-based Syndexa Pharmaceuticals has garnered $15 million in a second round of financing. VC report

> Myriad Genetics' stock continues to fall as investors fear poor results from a late-stage study of Flurizan for Alzheimer's. Myriad report

 > In a head-to-head study against Sanofi's Lovenox, Bayer and J&J's oral anti-clotting drug rivaroxaban proved superior in preventing venous blood clots in patients who underwent total knee replacement surgery. Report

Emerging Drug Developer: Kythera Biopharmaceuticals

And Finally... No frozen yogurt for Minnesota docs at Eli Lilly's ASCO booth. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.